FDA approves Agios Pharmaceuticals’ Tibsovo for targeted acute myeloid leukemia treatment
The US Food and Drug Administration (FDA) has granted approval to Agios Pharmaceuticals for Tibsovo (ivosidenib), designed for the treatment of acute myeloid leukemia (AML) in patients exhibiting specific genetic mutations and whose condition is either relapsed or refractory. This marks a significant advancement in the targeted therapy landscape for AML. Tibsovo, an isocitrate dehydrogenase-1 […]